DR. PETER R GRAZE M.D. NPI 1669400784

NPI Details

DR. Peter R Graze, M.D. is a hematology and oncology internal medicine in Annapolis, MD with 55 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Peter R Graze, M.D. NPI is 1669400784. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: HARVARD MEDICAL SCHOOL
Graduation Year:1971

The provider's business location address is:

2003 MEDICAL PKWY
SUITE 210
ANNAPOLIS, MD
ZIP 21401-992
Phone: (410) 573-5300
Fax: (410) 266-9645

The NPI 1669400784 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Collection of blood sample from implanted device (HCPCS:36591)
• Unclassified drugs (HCPCS:J3490)
• Uric acid level, blood (HCPCS:84550)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Administration of prolonged chemotherapy into vein (HCPCS:96416)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Drawing of blood for a medical problem (HCPCS:99195)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Beta-2 microglobulin (protein) level (HCPCS:82232)

The enumeration date for this NPI number is 6/29/2006 and was last updated on 12/3/2013.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.